title: Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases.
abstract: The results of treating 12 consecutive patients with unresectable colorectal hepatic metastases with a hepatic arterial infusion of high-dose Adriamycin, 100-120 mg/m2, using hepatic venous isolation (HVI) and charcoal hemoperfusion (CHP) are reported herein. Adriamycin was administered over 5-15 min under extracorporeal drug elimination by HVI-CHP. HVI was percutaneously accomplished by either the double-balloon technique using a Fogarty occlusion catheter (8/22F) or a balloon-tipped catheter (16F). During the infusion, isolated hepatic venous blood was filtered by CHP and pumped into the left axillary vein. There were no lethal complications, and good hemodynamic tolerance to HVI-CHP was confirmed. Tumor liquefaction accompanied by a sharp decrease in serum carcinoembryonic antigen levels by more than 50% of pretreatment levels was observed in 6 of the 12 patients 1 month after treatment. Apart from chemical hepatitis, which developed in 11 (92%) of the patients, the Adriamycin toxicities were well controlled following the development of nausea and vomiting in 2 patients (17%), leukopenia < 2,000/mm3 in 3 (25%), and gastric ulcer in 1 (8%). These results indicate that this method is a safe and useful procedure for otherwise hazardous high-dose intra-arterial chemotherapy in patients with unresectable hepatic tumors.
authors.affiliation: First Department of Surgery, Kobe University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ku
authors.forename: M
authors.initials: M
authors.lastname: Tominaga
authors.forename: T
authors.initials: T
authors.lastname: Iwasaki
authors.forename: T
authors.initials: T
authors.lastname: Kitagawa
authors.forename: I
authors.initials: I
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Shiotani
authors.forename: S
authors.initials: S
authors.lastname: Kusunoki
authors.forename: Y
authors.initials: Y
authors.lastname: Maekawa
authors.forename: M
authors.initials: M
authors.lastname: Samizo
authors.forename: T
authors.initials: T
authors.lastname: Fukumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kuroda
authors.forename: S
authors.initials: S
authors.lastname: Hirota
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002404:Catheterization; D002606:Charcoal / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000503:physiopathology; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006439:Hemodynamics; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; D002606:Charcoal; D004317:Doxorubicin